There have been almost no scientific studies of the effectiveness of HIV pre-exposure prophylaxis (PrEP) in central or eastern Europe. However, a recent study of 887 PrEP users, all gay and bisexual men, in the Polish city of Wroclaw, found only nine HIV infections (1% of PrEP users) over a three-year period from 2020 to 2023.
All 887 PrEP users took oral tenofovir disoproxil/emtricitabine (TDF/FTC) pills. Strikingly, there were no HIV infections in men currently taking them daily; all were in men who had chosen to take event-based PrEP, apart from one in a man who had recently stopped daily use. As elsewhere, the prescribed regimen for event-based dosing is the ‘2-1-1’ pattern: a double dose taken before having sex, followed by a single dose 24 hours after that if sex does happen, and another 24 hours after that.
There did not appear to be any infections in men who were taking 2-1-1 PrEP correctly at the time. Specifically, the authors say, seven of the nine infections were associated with failure to take the double dose of PrEP before sex.
Read the full news story at aidsmap.
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.